Other analysts, such as Barclays Capital and Deutsche Bank, have also raised their targets for the company, which provides services for medication errors and hospital-acquired infections. CareFusion also maintains a consensus “Buy” rating and a price target of $34.27, according to the report.
More Articles on Infection Control:
Study: Cloth Towels Insufficient to Clean Hospital Rooms
Study: Printed Surgical Safety Checklist Improves Item Validation Rate
7 Action Items for Enhancing Patient Safety Data
